[Skip to Content]
[Skip to Content Landing]
Views 78
Citations 0
Invited Commentary
February 7, 2019

Understanding Ocular Inflammation in Eyes Treated With Intravitreal Gene Therapy

Author Affiliations
  • 1Department of Ophthalmology, University of California, San Francisco
JAMA Ophthalmol. Published online February 7, 2019. doi:10.1001/jamaophthalmol.2018.6915

Inherited eye diseases typically cause progressive, irreversible vision loss, with limited effective treatments. Recently, a trial of the first US Food and Drug Administration–approved gene therapy for inherited eye disease demonstrated the safety of gene therapy.1 Diseases that affect the inner retinal ganglion cells, such as Leber hereditary optic neuropathy, may be targeted using an intravitreal rather than subretinal injection. Vectors that can be delivered intravitreally are being developed to target the outer retina, which may cause less photoreceptor damage2 but may have a greater risk of systemic exposure to the viral vector used to deliver the genetic material with accompanying inflammation.3